NASDAQ:SAGE - SAGE Therapeutics Stock Price, News & Analysis

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, topping analysts' consensus estimates of ($3.32) by $0.04. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.27 million. The business's revenue for the quarter was down 99.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.36) EPS. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for SAGE Therapeutics.

14 analysts have issued 12 month target prices for SAGE Therapeutics' stock. Their forecasts range from $80.00 to $261.00. On average, they expect SAGE Therapeutics' share price to reach $200.2727 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

News coverage about SAGE stock has trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SAGE Therapeutics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), Twitter (TWTR), Johnson & Johnson (JNJ), Celgene (CELG) and Gilead Sciences (GILD).

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (15.30%), Vanguard Group Inc. (8.92%), Jennison Associates LLC (5.72%), BlackRock Inc. (5.32%), Invesco Ltd. (3.91%) and Janus Henderson Group PLC (3.66%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Farallon Capital Management LLC, Strs Ohio, Senator Investment Group LP, Candriam Luxembourg S.C.A. and Bank of America Corp DE. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Jennison Associates LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, BlackRock Inc., Amundi Pioneer Asset Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $162.00.

SAGE Therapeutics has a market capitalization of $8.37 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]